Thus, we observe the increasing incidence of BCBM that occur mostly in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and triple-negative breast cancer [2,3,4,5]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.